Fate Therapeutics (FATE) EBIT (2012 - 2026)
Fate Therapeutics (FATE) reported EBIT of -$33.0 million for Q1 2026, up 20.06% on a YoY basis from -$27.5 million in Q1 2025, and up 4.96% quarter-over-quarter from -$34.7 million in Q4 2025.
Fate Therapeutics (FATE) EBIT (2012 - 2026) Analysis & Trends
Fate Therapeutics has reported EBIT for 15 years, with the latest figure at -$33.0 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 20.06% year-over-year to -$33.0 million; the trailing twelve-month figure through Mar 2026 stood at -$139.4 million (up 30.46% YoY), and the FY2025 full-year result was -$147.7 million, up 29.76% from the prior year.
- EBIT for Q1 2026 stood at -$33.0 million, up from -$34.7 million in the prior quarter.
- The five-year high for EBIT was -$28.6 million in Q1 2023, with the low at -$86.4 million in Q3 2022.
- Historically, EBIT has averaged -$52.3 million across 5 years, with a median of -$51.1 million in 2024.
- Annual changes were most pronounced in 2023 — EBIT soared 61.6% — and 2024, when it tumbled 78.61%.
- Fate Therapeutics' EBIT stood at -$64.4 million in 2022, then rose by 25.37% to -$48.1 million in 2023, then fell by 28.44% to -$61.7 million in 2024, then jumped by 43.77% to -$34.7 million in 2025, then rose by 4.96% to -$33.0 million in 2026.
- The last three EBIT figures came in at -$33.0 million (Q1 2026), -$34.7 million (Q4 2025), and -$34.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Fate Therapeutics | 250.86 Mn | 250.86 Mn | - | -33.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.00 Mn |
| Dec 31, 2025 | -34.72 Mn |
| Sep 30, 2025 | -34.74 Mn |
| Jun 30, 2025 | -36.97 Mn |
| Mar 31, 2025 | -41.28 Mn |
| Dec 31, 2024 | -61.75 Mn |
| Sep 30, 2024 | -52.38 Mn |
| Jun 30, 2024 | -45.08 Mn |
| Mar 31, 2024 | -51.07 Mn |
| Dec 31, 2023 | -48.08 Mn |
| Sep 30, 2023 | -51.28 Mn |
| Jun 30, 2023 | -62.57 Mn |
| Mar 31, 2023 | -28.59 Mn |
| Dec 31, 2022 | -64.42 Mn |
| Sep 30, 2022 | -86.39 Mn |
| Jun 30, 2022 | -83.11 Mn |
| Mar 31, 2022 | -74.47 Mn |
| Dec 31, 2021 | -69.38 Mn |
| Sep 30, 2021 | -54.62 Mn |
| Jun 30, 2021 | -46.78 Mn |